Penn Vet parasitologist Boris Striepen wins 2027 Wang Award

Version 2 — Full analysis

Boris Striepen, PhD, of the University of Pennsylvania’s School of Veterinary Medicine has been named the 2027 recipient of the Alice & C.C. Wang Award in Molecular Parasitology, one of ASBMB’s field-specific honors recognizing major contributions to parasite biology. The society said Striepen’s work transformed Cryptosporidium research by developing genetic tools and experimental models that made the parasite far more accessible to mechanistic study. (asbmb.org)

The recognition builds on a long arc of work in molecular parasitology. Striepen joined Penn Vet in 2017 and holds the Mark Whittier and Lila Griswold Allam Professorship in Microbiology and Immunology. His lab has focused on the cell and molecular biology of apicomplexan parasites, with a particular emphasis on Cryptosporidium, a pathogen that causes cryptosporidiosis and has historically been difficult to culture and genetically manipulate. Penn has also highlighted his prior honors, including the William Trager Award and an NIAID MERIT Award. (vet.upenn.edu)

A key inflection point came in 2015, when Striepen and colleagues reported genetic modification of Cryptosporidium parvum in Nature. That paper described a workable genetic system for a pathogen that, at the time, had no vaccine and only one approved drug option, nitazoxanide. Subsequent work from the lab expanded the toolkit further, including studies on sexual development, virulence, and parasite proteins exported into host cells. Taken together, those advances helped move Cryptosporidium from a technically stubborn organism to one that can be studied with modern molecular methods. (nature.com)

ASBMB’s announcement frames the award in those terms, saying Striepen’s research enabled investigators to probe parasite biology, identify drug and vaccine targets, and advance treatment development. The Wang Award itself was established to raise the profile of molecular parasitology within the broader biochemistry and molecular biology community, and the 2027 honorees are expected to present at the ASBMB Annual Meeting in Boston on April 3–6, 2027. (asbmb.org)

While public expert reaction to this specific award appears limited so far, the broader field has long treated Striepen’s contributions as foundational. A Nature News & Views item on the 2015 paper described the work as bringing CRISPR-based genetic manipulation to Cryptosporidium, and Penn’s own faculty profile points to that study as a landmark in the field. Inference: awards like this often recognize not just a single discovery, but the creation of methods that allow many other labs to make progress. That appears to be the case here. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this is basic science with practical downstream relevance. Cryptosporidium sits at the intersection of companion animal, livestock, public health, and One Health concerns. In production animal settings, cryptosporidiosis remains a familiar cause of neonatal diarrhea, especially in calves, and the organism’s environmental persistence and fecal-oral transmission make prevention and control difficult. On the human side, WHO identifies diarrheal disease as a leading cause of child mortality, and Cryptosporidium is among the important parasitic contributors. Better molecular tools matter because they can improve target discovery, clarify host-pathogen interactions, and strengthen the evidence base for future therapeutics. (who.int)

For clinicians and veterinary researchers, the bigger signal may be that parasitology remains a strategically important research area, even when the immediate headline is an academic award. Recognition from a major scientific society can help attract trainees, grant support, and cross-disciplinary attention, all of which can accelerate progress in a field where translational options have historically been limited. That’s especially relevant for enteric parasites that affect both animal populations and vulnerable human communities. (asbmb.org)

What to watch: The next milestone is Striepen’s expected lecture at the 2027 ASBMB Annual Meeting, where the field may get a clearer view of which Cryptosporidium questions are moving closest to translational payoff, including drug development, virulence biology, and immune interaction studies. (asbmb.org)